Home>News> Evonik puts down $41M to expand North American CDMO capabilities for injectables

Evonik puts down $41M to expand North American CDMO capabilities for injectables

Germany-headquartered specialty chemicals company Evonik is investing €35 million ($40.8 million) to expand its CDMO facilities in Alabama and Vancouver, Canada, to meet growing demand for controlled release injectable formulations.
 
Following more than $50 million of investment over the last four years in its Birmingham, Alabama site, Evonik is constructing a new 31,000-square-foot building there to increase the production capacity of its Resomer polymers. These bioresorbable materials, acquired by Evonik from Boehringer Ingelheim back in 2011, are used in extended-release parenteral drug delivery systems and medical devices.

Tags: